Randall Michael Giuffre - Jun 1, 2023 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy E. Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jun 1, 2023
Transactions value $
$0
Form type
4
Date filed
6/2/2023, 04:02 PM
Previous filing
Jan 3, 2023
Next filing
Jun 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 295K Jun 1, 2023 Direct F1
holding DMAC Voting Common Shares, no par value per share 25.6K Jun 1, 2023 See footnote F2
holding DMAC Voting Common Shares, no par value per share 21.1K Jun 1, 2023 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +17K $0.00 17K Jun 1, 2023 Common Shares 17K $2.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,146 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan, 64,959 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, 164,890 voting common shares held by Michael Giuffre and his wife jointly and 61,360 voting common shares held by Michael Giuffre individually.
F2 These voting common shares are held by 424822 Albert Ltd, of which Michael Giuffre has sole voting and dispositive power.
F3 Vests in four nearly equal quarterly installments over one year.